目的:研究细胞间黏附分子-1(IC A M-1)在肝细胞肝癌(H CC)中表达的临床意义。方法:应用免疫组化方法结合全自动图像检测40例H C C组织及其癌旁组织和28例肝硬化组织中IC A M-1的表达,以酶联免疫吸附实验(E LISA)法测定42例H C C、26例...目的:研究细胞间黏附分子-1(IC A M-1)在肝细胞肝癌(H CC)中表达的临床意义。方法:应用免疫组化方法结合全自动图像检测40例H C C组织及其癌旁组织和28例肝硬化组织中IC A M-1的表达,以酶联免疫吸附实验(E LISA)法测定42例H C C、26例肝硬化患者和22例正常健康者血清中可溶性细胞间黏附分子-1(sIC A M-1)的水平,并与甲胎蛋白(A FP)进行同步分析。结果:40例H C C组织IC A M-1表达阳性率为80.0%,高于癌旁和肝硬化组织(P<0.05),阳性率与组织学分类相关。H C C组织中IC A M-1含量高于癌旁及肝硬化组织(P<0.05),转移组H C C中IC A M-1的含量也高于非转移组(P<0.05),而癌旁及肝硬化组织中含量差异无显著性(P>0.05)。H C C患者血清sIC A M-1水平高于肝硬化及正常健康组(P<0.05),H C C伴转移组患者血清中sIC A M-1水平高于无转移组(P<0.05),A FP阴性组与阳性组sIC A M-1水平差异无显著性(P>0.05)。结论:H C C组织中高度表达IC A M-1和血清中高水平的sIC A M-1,在一定程度上可以反映H C C发展程度及转移状态,IC A M-1有可能作为H C C的一个新的诊断指标。展开更多
Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Most of patients present with advanced disease that cannot be treated with curative or ablative intent. The aim of the study was to ...Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Most of patients present with advanced disease that cannot be treated with curative or ablative intent. The aim of the study was to assess the therapeutic benefit of concurrent chemoradiotherapy (CCRT) in patients with advanced HCC and to identify factors that predict OS. Methods: Patients with radiologically or biopsy proven primary HCC from 2010 to 2013 were included in the study. Gemcitabine was given in a dose of 70 mg/m2 once weekly for three weeks during external beam radiotherapy 30 Gy/2 Gy/fraction/five fractions per week in the Clinical Oncology Department, Assiut, Egypt. Results: Forty-nine patients were eligible but forty patients were evaluable for assessment. The partial response rate (PR) was 35% (14 patients), 16 patients (40%) had stable disease (SD) and the progressive disease was 25%. Painful hepatomegaly was significantly relieved in 70% of patients. Transaminases rose as grade 3 toxicity in 15% of patients. Longer overall survival (OS) was significantly observed in patients with performance status 0, child-Pugh A, Barcelona Clinic Liver cancer Stage B, PR and α fetoprotein level decrement. Conclusion: Concurrent chemoradiotherapt provides an acceptable response and palliation of pain in advances HCC. Our findings showed that better survival for patients with good performance and liver functions.展开更多
文摘目的:研究细胞间黏附分子-1(IC A M-1)在肝细胞肝癌(H CC)中表达的临床意义。方法:应用免疫组化方法结合全自动图像检测40例H C C组织及其癌旁组织和28例肝硬化组织中IC A M-1的表达,以酶联免疫吸附实验(E LISA)法测定42例H C C、26例肝硬化患者和22例正常健康者血清中可溶性细胞间黏附分子-1(sIC A M-1)的水平,并与甲胎蛋白(A FP)进行同步分析。结果:40例H C C组织IC A M-1表达阳性率为80.0%,高于癌旁和肝硬化组织(P<0.05),阳性率与组织学分类相关。H C C组织中IC A M-1含量高于癌旁及肝硬化组织(P<0.05),转移组H C C中IC A M-1的含量也高于非转移组(P<0.05),而癌旁及肝硬化组织中含量差异无显著性(P>0.05)。H C C患者血清sIC A M-1水平高于肝硬化及正常健康组(P<0.05),H C C伴转移组患者血清中sIC A M-1水平高于无转移组(P<0.05),A FP阴性组与阳性组sIC A M-1水平差异无显著性(P>0.05)。结论:H C C组织中高度表达IC A M-1和血清中高水平的sIC A M-1,在一定程度上可以反映H C C发展程度及转移状态,IC A M-1有可能作为H C C的一个新的诊断指标。
文摘Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Most of patients present with advanced disease that cannot be treated with curative or ablative intent. The aim of the study was to assess the therapeutic benefit of concurrent chemoradiotherapy (CCRT) in patients with advanced HCC and to identify factors that predict OS. Methods: Patients with radiologically or biopsy proven primary HCC from 2010 to 2013 were included in the study. Gemcitabine was given in a dose of 70 mg/m2 once weekly for three weeks during external beam radiotherapy 30 Gy/2 Gy/fraction/five fractions per week in the Clinical Oncology Department, Assiut, Egypt. Results: Forty-nine patients were eligible but forty patients were evaluable for assessment. The partial response rate (PR) was 35% (14 patients), 16 patients (40%) had stable disease (SD) and the progressive disease was 25%. Painful hepatomegaly was significantly relieved in 70% of patients. Transaminases rose as grade 3 toxicity in 15% of patients. Longer overall survival (OS) was significantly observed in patients with performance status 0, child-Pugh A, Barcelona Clinic Liver cancer Stage B, PR and α fetoprotein level decrement. Conclusion: Concurrent chemoradiotherapt provides an acceptable response and palliation of pain in advances HCC. Our findings showed that better survival for patients with good performance and liver functions.
